1. Xu X, Gan M, Ge Y, Yi C, Feng T, Liu M, Wu C, Chen X, Zhang W*, Zhao L*, Zou J*. Multifaceted glycoadjuvant@AuNPs inhibits tumor metastasis through promoting T cell activation and remodeling tumor microenvironment. J Nanobiotechnology. 2021. 19(1): 376. (Corresponding author)
2. Xu X, Yi C, Yang X, Xu J, Sun Q, Liu Y, Zhao L. Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine. Mol Ther Oncolytics. 2019. 14:213-221. (Corresponding author)
3. Xu Xiaojing, Jin Ziqi, Liu Yonghao, Gong Huanle, Sun Qing, Zhang Weidong, Zhao Lixiang*. Carbohydrate-based adjuvants activate tumor-specific Th1 and CD8+ T-cell responses and reduce the immunosuppressive activity of MDSCs. Cancer Letters. 2019. 440: 94~105. (Corresponding author)
4. Mei Yu, Zhao Lixiang#, Yonghao Liu, et al. Combining DNA Vaccine and AIDA-1 in Attenuated Salmonella Activates Tumor-Specific CD4(+) and CD8(+) T-cell Responses. Cancer Immunology Research. 2017. 5(6):503-514. (Equal contributor)
5. Xu Xiaojing, Mei Yu, Zhao Lixiang*. Newcastle disease virus co-expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy. Cancer Science. 2018.109(2): 279. (Corresponding author)
6. Zhao Lixiang, Mei Yu, Sun Qing, et al. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response. The Journal of Immunology.2014. 193(2): 735-745.
7. Xu Xiaojing, Sun Qing, Yu Xiao,Zhao Lixiang*. Rescue of nonlytic Newcastle Disease Virus (NDV) expressing IL-15 for cancer immunotherapy. Virus Research. 2017. 233:35-41.
8. Xu Xiaojing, Chen Xiang, Gao Song, Zhao Lixiang*. Pathogenicity of FtsK mutant of avian pathogenic Escherichia coli 2016. 60(1): 13~18. (Corresponding author）
9. Sun Qing#, Zhao Lixiang#, Song Qingqing, et al. Hybrid- and complex-type N-glycans are notessential for Newcastle disease virus infection and fusion of host cells. Glycobiology. 2012. (Equal contributor)
10. Zhao L, Liu H. Newcastle disease virus: a promising agent for tumor immunotherapy. Clin Exp Pharmacol Physiol. 2012; 39(8): 725-30.
11. Zhao L, Gao S, Huan H,Xu X, Zhu X, Yang W, Gao Q, Liu X.Comparison of virulence factors and expression of specific genes between uropathogenic Escherichia coli and avian pathogenic E. coli in a murine urinary tract infection model and a chicken challenge model. Microbiology. 2009; 155: 1634-1644.
发明专利
1. 赵李祥，梅雨，刘海燕。以减毒沙门氏菌为载体的口服肿瘤疫苗的制备及其应用。专利号：CN201310600070.6 （授权时间：2015年）
2. 赵李祥，刘海燕，文丽君。一种重组新城疫病毒修饰的自体肿瘤疫苗的制备及其应用。专利号：CN201110188380.2（授权时间：2013年）